RG6810 / Innovent Biologics, Roche, Fortvita Biologics - LARVOL DELTA

A multicenter, open-label phase I study of IBI3009 monotherapy or in combination with other antitumor therapies in extensive-stage small cell lung cancer. (clinicaltrials.gov) - P1 | N=67 | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | N=43 ➔ 67

Enrollment change • Monotherapy • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

CIBI3009A101: Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer (clinicaltrialsregister.eu) - P1/2 | N=20 | Not yet recruiting | Sponsor: Fortvita Biologics (USA) Inc.

New P1/2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=190 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Sep 2024 ➔ Dec 2024

Enrollment open • Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate (PRNewswire) - "Innovent Biologics...announced a collaboration and exclusive license agreement with Roche...to advance the development of IBI3009, a novel DLL3-targeted antibody drug conjugate (ADC) candidate. IBI3009 has already obtained IND approvals in Australia, China, and the U.S., with the first patient for the Phase 1 study dosed in December 2024. This collaboration aims to bring innovative treatment options to patients with advanced small cell lung cancer....IBI3009 targets DLL3, an antigen with low expression in normal tissues but significantly overexpressed in certain cancers, particularly small-cell lung cancer and other neuroendocrine tumors."

Licensing / partnership • Trial status • Neuroendocrine Tumor • Small Cell Lung Cancer